ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BeOne Medicines AG (ONC) does not present a strong buy opportunity for a beginner, long-term investor at this moment. Despite some positive catalysts like the FDA orphan drug designation and a strong growth outlook for its flagship drug Brukinsa, the technical indicators, financial performance, and mixed analyst ratings suggest caution. The stock's pre-market price increase is not supported by strong technical or proprietary trading signals, and hedge fund selling adds further uncertainty.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 35.181, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 281.931, with resistance at 290.198 and support at 273.665. This indicates limited upside potential in the short term.
FDA orphan drug designation for BGB-B2033 enhances the company's oncology portfolio.
Strong growth outlook for Brukinsa, with analysts noting it as a category-leading drug.
Recent price target increases by multiple analysts, with targets as high as $425.
Hedge funds are selling the stock, with a significant increase in selling activity (7307.41%).
Mixed analyst ratings, including a downgrade from Jefferies citing limited upside at current levels.
Weak financial performance in Q3 2025, with net income and EPS declining significantly YoY.
In Q3 2025, revenue increased by 41% YoY to $1.41 billion, indicating strong top-line growth. However, net income dropped by -202.88% YoY to $124.84 million, and EPS fell by -188.89% YoY to 0.08, reflecting significant profitability challenges. Gross margin improved slightly to 86.09%, up 3.75% YoY.
Analyst ratings are mixed. Wolfe Research initiated coverage with an Outperform rating and a $340 price target, citing a strong development pipeline. However, Jefferies downgraded the stock to Hold with a $290 price target, citing limited upside. Other analysts have raised price targets, with the highest being $425, but concerns about slower growth in new assets persist.
